The Company announces discontinuation of the Phase II Study of OBI-888

1.Date of occurrence of the event:2022/07/01 2.New drug name or code:Passive Immunotherapeutic Monoclonal Antibody, OBI-888 3.Indication:An immunotherapeutic monoclonal antibody targeting Globo H for the treatment of cancer. Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/show/NCT03573544 https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B1%5D=6213 4.Planned development stages:Phase I, II, III clinical trial, and New Drug Application (NDA) 5.Current development stage: (1)Application submission/approval/disapproval/each of clinical trials(include interim analysis): OBI-888 is […]